Coherus BioSciences, Inc. (NASDAQ:CHRS), a commercial-stage biopharmaceutical company with a market capitalization of approximately $149 million, has undergone a significant transformation in recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback